Overview

Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, three-period sequential dosing study being conducted to determine the pharmacokinetics of Triferic iron administered intravenously (IV) to healthy adults.
Phase:
Phase 1
Details
Lead Sponsor:
Rockwell Medical Technologies, Inc.
Treatments:
Citric Acid
Iron